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Abstract 
While schizophrenia and mental health are qualitatively distinct at the level of clinical presentation, 
the specific molecular signatures that underlie, or associate with, illness are not. Biomarker 
identification in schizophrenia is intended to offer a number of important benefits to patient well-
being including prediction of future illness, diagnostic clarity and a level of disease description that 
would guide treatment choice. However, the choice of sample and form of analysis used to produce 
useful biomarkers is still uncertain. In this review, advances from recent studies spanning the 
technical spectrum are presented together with comment on their comparative strengths and 
weaknesses.  To date, these studies have aided our understanding of the pathological processes 
associated with illness much more than they have provided robust biomarkers. A number of reasons 
for this observation are suggested, as are new strategies for the extraction of biomarkers from large 
 ?-ŽŵŝĐƐ ?ĚĂƚĂƐĞƚƐ ? 
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Introduction 
One of the goals of schizophrenia research is to define the disorder in clear and simple biological 
terms and, in so doing, relegate it to the catalogue of mundane  ? and more tractable - human 
disorders. The current pace of developments in large-scale biological data acquisition and processing 
might make the task appear eminently achievable. However, even the most fervent optimists among 
us would have to admit that, despite this effort, we are still piecing together the edge of the jigsaw 
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puzzle rather than seeing the full picture. Contrast this situation ǁŝƚŚƚŚĂƚŽĨWĂƌŬŝŶƐŽŶ ?ƐĚisease  ? a 
cousin-by-neurotransmitter of schizophrenia. A cross-disciplinary understanding of environmental 
influences, genetic risk, cellular pathology, anatomical pathology, network dysfunction, and outward 
symptomatology have converged to inform the development of novel therapies. Multiple 
explanations have been put forward for this qualitative difference in disorder complexity, with most 
focused on the idea that schizophrenia is not a unitary disorder but rather the common symptomatic 
end-point of a great variety of brain dysfunctions and insults. In support of this, schizophrenia now 
belongs to a wide family of disorders that have demonstrated interrelationships at the level of 
genetics. These include bipolar disorder, depression, epilepsy, intellectual disability, autism 
spectrum disorders and, recently, multiple sclerosis [Consortium, 2013, Lee et al., 2013, Andreassen 
et al., 2014, Mccarthy et al., 2014, Ruderfer et al., 2014]. Hence, the aetiopathology of one 
individual ?s schizophrenia is unlikely to be the same as that of the next individual; and two people 
with similar aetiologies may diverge at the level of diagnosis [Corvin, 2012]. These features should 
actively shape any analytical approaches: both in terms of the necessity for increased sample sizes in 
any form of a case-control study, and the need for new approaches to tease out pathologies relevant 
to the individual as well as the population. Biomarker identification is one such field of research that 
will have to meet these demands. 
Biomarkers are the molecular, functional, anatomical, or physiological signs that can be 
translationally harnessed to predict or confirm a particular diagnosis, or suggest or monitor a 
particular treatment strategy. A recent review [Weickert et al., 2013] has succinctly described the 
importance of these applications of biomarkers in the context of schizophrenia diagnosis and 
treatment.  The progress in development of commercial schizophrenia biomarker tests depends on 
economic models, regulation and perceived healthcare need, just as much as bioinformatics. Hence, 
there may be a more pragmatic short-term goal for biomarkers: to help sub-divide and classify 
schizophrenia according to its principal molecular aetiopathologies. 
Biomarkers could be considered to extend all the way to include our fixed genomic attributes. 
However, it is perhaps more useful to consider only those quantifiable features that display a 
potential for response and variation in the lifetime. Schizophrenia researchers have searched for 
biomarkers in altered morphology and representation of specific CNS cell types in post mortem 
tissue, structural and functional brain imaging, externally measured electrophysiological properties, 
cognitive performance, and various dimensions of the psychiatric phenotype. At the sub-cellular and 
tissue levels, the search has queried the transcriptomic, proteomic, metabolomic, immunological, 
and epigenetic levels of biology. It is this second group of potential biomarkers that will be covered 
in this review. Particular attention will be paid to new methods (e.g. epigenetics) and the larger-scale 
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studies which avoid sample size issues. Additionally,  the current state of biomarker discovery in 
other disorders will be briefly mentioned in order to highlight the distance that schizophrenia has 
left to travel. 
 
Transcriptomics 
The search for gene expression changes associated with schizophrenia is the most worn research 
path towards biomarker identification.  However, despite the efforts of many laboratories, the 
transcriptomics of cancer, for example, is still considerably further progressed. A commercially and 
clinically viable test, Oncotype DX (Genomic Health, US), can now generate a risk value for the re-
occurrence of breast cancer (and thus guide follow-on monitoring and treatment) based on the 
analysis of 21 genes [Paik et al., 2004]. Schizophrenia has some way to go to match this, but the field 
has generally appreciated the need for large sample sizes to compensate for its complex and 
heterogeneous nature. Transcriptomics studies in schizophrenia have either focused on the ease of 
access to blood samples - and their downstream translational potential  ? or the pathological 
relevance offered by post mortem brain tissue. The use of blood transcriptomics for the purpose of 
disease diagnosis and patient stratifications has been recently reviewed [Kumarasinghe et al., 2012, 
Mamdani et al., 2013] and so here only particularly illuminating examples will be discussed. These 
are followed by the latest individual and meta-analyses from post mortem cortex samples. 
In one study, whole blood was obtained from 52 antipsychotic-naive schizophrenia patients and 49 
healthy controls [Takahashi et al.]. 792 differentially expressed genes were discovered through 
microarray analysis and the process of cell adhesion identified as a significantly over-represented 
gene ontology term within. A neural network approach was then adopted in order to define a 
diagnostic set of genes. This set comprised CINP, TDRD9, DAOA, PGRMC1, NAF1, LIPH, MAP1D, and 
INSL3, and had the power to correctly diagnose samples with 88% accuracy. In another study, blood 
gene expression was profiled in patients diagnosed with schizophrenia that were being treated with 
clozapine (n=10), risperidone (n=10) or haloperidol (n=8), and compared to gene expression profiles 
of healthy controls (n=10) [Maschietto et al., 2012]. Six genes that were identified on the basis of 
disease-specific gene expression changes (HERPUD1, HOXA13, CTNNA1, SULT1A1, PIK3R3 and 
MALAT1) were used as the basis for a diagnostic test. This was able to correctly identify disease 
status in 89.3% of cases of schizophrenia and 70% of healthy controls. However, this assessment was 
carried out in the same set of samples and controls - meaning its use is still to be truly tested. Next 
generation RNA-seq was used to analyse differential gene expression differences in blood from 36 
drug-naive schizophrenia patients and 40 healthy controls [Sainz et al., 2013]. Of the 200 genes 
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identified, some overlapped with genome-wide association studies of the disorder (including 
CSMD1, EHF, and RFX2), and others had been previously described in schizophrenia literature 
(GRIK3, LPL, S100B, SNCA, SYN2, TUBB2A, and SELENBP1). Gene ontology enrichment in the 
differentially expressed genes suggested a key role for wounding, and acute inflammatory and 
innate immune response. A larger study assessed gene expression changes in peripheral blood 
mononuclear cells taken from 114 cases of schizophrenia or schizoaffective disorder and 80 healthy 
controls [Gardiner et al., 2013]. The genes EIF2C2, EVL, DEFA4, S100A12, PI3, and MEF2D all showed 
validated expression changes in this cohort and, overall, a strong indication of a role for immune 
gene involvement in schizophrenia was described. Transcriptomic analysis of a large set of blood 
samples from 121 individuals diagnosed with schizophrenia (29 of whom were anti-psychotic 
treatment free) and 118 healthy controls was recently published [De Jong et al.]. Their analysis 
differed from the standard  ?ranked ?Žƌ  ?ĨŽůĚ-ĐŚĂŶŐĞ ?ĂƉƉƌŽĂĐŚes, and instead used Weighted Gene 
Co-expression Network Analysis in which  ?ŵŽĚƵůĞƐ ? of genes are identified that co-vary in expression 
between cases and controls. Two identified modules strongly associated with the disease state were 
replicated in an antipsychotic-free dataset, and were highly enriched in brain genes. They included 
the genes ABCF1, SLC2A6, SDHA, DHRS1, sep-06, CNDP2, SIGIRR, FBXL5, and DHX58. These data 
possessed several interesting features. Firstly, there was a profound effect of medication on gene 
expression, indicating that treatment-response related biomarkers may be readily achievable, but at 
the cost of the identification of disease-specific biomarkers. Secondly, the fact that the two 
replicated modules were significantly enriched for brain genes confirms the relevance of blood 
analysis for the investigation and diagnosis of brain dysfunction. In fact, independent studies have 
confirmed this point [Harris et al., 2012] . Lastly, one module contained numerous circadian genes 
that most likely relate to the time of blood sample collection [Whitney et al., 2003]. This is a 
technical issue that should be factored into any clinical biomarker study.  
A parallel study also used co-expression modules [Chen et al., 2012]. However, the authors studied 
post mortem prefrontal cortex samples from those diagnosed with schizophrenia (n=45) and healthy 
controls (n=46) and identified two modules centred around the NOTCH2 and MT1X genes, 
respectively, that were associated with the diagnosis of schizophrenia. Ontology analysis of the two 
modules revealed significant signatures for neuronal differentiation/development and 
metallothioneins/metal-binding proteins, respectively. A meta-analysis was conducted on data from 
microarray studies of the dorsolateral prefrontal cortex comprising 107 patients with schizophrenia 
and 118 healthy subjects [Perez-Santiago et al., 2013]. The expression of genes BAG3, C4B, EGR1, 
MT1X, NEUROD6, SST, and S100A8 was found to be significantly altered in schizophrenia. Note that 
the gene MT1X is shared between this study and that of Chen et al. described above: but also note 
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that MT1X and S100A8 were pinpointed in this study as genes whose regulation probably reflects 
anti-psychotic treatment rather than disease status. A second meta-analysis combined gene 
expression studies of prefrontal cortex from 153 patients diagnosed with schizophrenia and 153 
healthy controls. It also used co-expression analysis models to identify gene ontologies contributing 
to disease pathology [Mistry et al., 2013]. Upregulated genes included SMG1, PLOD2, LPL, RHOBTB3, 
BBX, EIF2C2, FTL and P4HA1. Downregulated genes included NECAB3, RFTN1, HBQ1, GNAL, PPA2, 
KCNK1, OPCML, OPN9, FBXO9, and RGS7. Analysis of the full set of significant genes indicated that 
altered energy metabolism and immune response were probable key pathologies. The co-expression 
analysis picked up similar ontology themes but, based on the location of certain transcripts, was also 
able to assign pathologies to particular cell types. For example, oxidative phosphorylation, synaptic 
and ubiquitination deficits were assigned to neurons, immune and glutamine metabolism deficits to 
astrocytes, and myelination deficits to oligodendrocytes  ? thus increasing our cell-level 
understanding of pathologies. 
 
Epigenetics 
Epigenetics is the study of long-lasting modification of nuclear DNA (for example, methylation or 
nucleosome modification) that is often influenced by the environment and manifests itself as 
changes in gene expression. Recently reviewed [Nishioka et al., 2013], the study of global 
methylation changes associated with illness is the newest source of potential biomarkers for 
schizophrenia. As with genomics, transcriptomics and metabolomics, new analytical platforms (e.g. 
the Illumina Infinium HumanMethylation27 BeadChip array) as well as databases and resources are 
now available to aid biomarker discovery. Of particular interest is the brain-centric MethylomeDB 
which includes data from psychiatric disorders [Xin et al.].  
The methylation state of genomic DNA from the white blood cell genomes of 177 individuals 
diagnosed with schizophrenia and 171 healthy controls was recently studied [Melas et al.]. Global 
hypomethylation was observed in schizophrenia and was exacerbated in early-onset cases. 
Treatment with haloperidol, alone among the antipsychotics, was observed to return methylation to 
levels approaching normal. However, this analysis was carried out using methylation-sensitive 
restriction enzymes. Most studies, including those included below, apply bisulphite analysis and 
assess specific loci. Therefore, the general significance of global methylation, as opposed to locus-
specific methylation, has yet to be fully clarified. 
One study looked at methylation changes in DNA from post mortem frontal cortex samples from 35 
individuals diagnosed with bipolar disorder, 35 with schizophrenia and 35 healthy controls [Mill et 
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al., 2008]. Among their findings, hypermethylation was observed in the genomic loci associated with 
RPP21 (tRNA maturation pathway) and KEL (blood group). Hypomethylation was observed near 
WDR18 and GRIA2 (a glutamate receptor gene that has also been frequently linked with age-
dependent hypermethylation). In another study, 5 individuals diagnosed with schizophrenia, 7 with 
bipolar disorder and 6 healthy controls were assessed [Xiao et al.]. Over one thousand differentially 
methylated regions were identified, including overlaps with the data from Mill et al.. The authors 
also showed that local methylation changes clearly correlated with local gene expression changes. 
The identified methylation changes were over-represented in genes involved in synaptic 
transmission and axon guidance. A third study described the methylation analysis of white blood cell 
genomic DNA from 18 patients diagnosed with first-episode schizophrenia and from 15 healthy 
controls [Nishioka et al., 2013]. Methylation changes were largely associated with CpG islands in 
genes which were enriched for functions linked to the nuclear lumen, transcription factor binding, 
and nucleotide binding. Specific changes were observed for the catecholamine neurotransmission 
genes HTR1E and COMTD1. In another example, the analysis of 24 patients diagnosed with 
schizophrenia and 24 unaffected controls was described. Again, many thousands of differentially 
methylated regions were identified (~50% were hypermethylated, and often in the CpG island 
regions of gene promoters) [Wockner et al., 2014]. Significant overlaps with other genetic and 
 ?methylomics ? studies were reported, for example DRD2, NOS1, AKT1, HTR2A, SOX10, FOXP2, 
DTNBP1, NRG1, PPP3CC, BDNF, ZNF804A, NRGN, DRD4, MGST1, COMTD1 and GABRB2. Importantly, 
the multidimensional scaling employed to cluster individuals was not only able to partially resolve 
schizophrenia from control samples but also subdivided schizophrenia into two distinct groups. The 
clinical presentation of the two groups offered no clues as to the pathological basis of this separation 
but methylation levels at the schizophrenia candidate disease genes DTNBP1, COMT and DRD2 were 
distinct between the two. Finally, next generation sequencing was used to profile methylation-
enriched blood genomic DNA taken from very large cohorts of 750 individuals diagnosed with 
schizophrenia and 750 healthy controls [Aberg et al., 2013]. With such a large sample set it might be 
expected that the results would be clearer, but in fact they were more conservative than those 
described above. Particularly evident was how the age of the individual and various 
lifetime/environmental effects (e.g. smoking) appear to act as significant confounders to the 
interpretation of such data. However, replicated evidence was indeed found for altered methylation 
at the genes FNDC3B (involved in cell mobility) and DCTN2 (encoding a cytoskeleton remodelling 
protein that is known to interact with psychiatric illness candidate proteins GSK3ɴ and DISC1). 
 
Metabolomics 
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Metabolomics is the global study of body tissue or fluid constituents. Genomic variation, 
transcriptomic regulation, and environmental influence (e.g. drug treatment or life exerperience) all 
converge on metabolomic profile changes. Therefore, it offers a pragmatic means to interrogate 
state- and disease-dependent changes in patient samples.  A very recent example of metabolomics 
being successfully applied to blood samples comes from a study of Alzheimer ?s disease (AD) 
[Mapstone et al., 2014]. 525 elderly individuals were followed up over a 2-3 year period and, of this 
cohort, 74 showed progression to mild cognitive impairment (MCI) or AD. From the metabolomic 
profiling of blood from 53 of the  ?ĐŽŶǀĞƌƚĞƌƐ ? ĂŶĚ  ? ? ŚĞalthy non-converters, a simple logistic 
classifier model - based on phospatidylinositol, proline-asparagine dipeptide, glycoursodeoxycholic 
acid, and malic acid- was created and verified as 90% accurate in its prediction of conversion to an 
AD phenotype in a second validation sample set. In a related study, a proteomics test for AD using 
multiplexed bead-based bioassays has recently identified 10 plasma proteins (including 
transthyretin, clusterin, cystatin C, CC4 and ApoE) that have an 87% accuracy to predict transition to 
AD from MCI [Hye et al., 2014]. These two studies show that predictive tests based on 
metabolomic/proteomic analysis of blood can be a powerful clinical tool facilitating a rapid and 
tailored therapeutic response for neurological disorders. 
A number of high-quality studies have now queried the schizophrenia metabolome. They have 
demonstrably outperformed the transcriptomic studies in terms of consistency and biological 
informativeness. For example, in one study, blood plasma analysis was carried out on 103 lipid, 
amino acids and carnitine metabolites from 216 healthy controls and 265 schizophrenic patients [He 
et al., 2012]. Significant changes in this limited panel were observed for the amino acids arginine 
(decreased), glutamine (decr.), histidine (decr.) and ornithine (increased)) as well as the lipid 
phosphatidylcholine (C38:6) (decr.). This phosphatidylcholine decrease was replicated in a second 
study in which a wide range of phosphatidylethanolamines and phosphatidylcholines were found to 
be reduced in drug naïve (n=20) and relapsed patients (n=20) compared to matched heathy controls 
(n=17) [Kaddurah-Daouk et al., 2012]. The authors suggest these changes might reflect the way in 
which schizophrenia alters phospholipase-mediated signal transduction pathway activity or an 
oxidative stress environment increasing lipid peroxidation. 
Gas chromatography-mass spectrometry was applied to identify metabolite marker profiles before 
and after treatment with the anti-psychotic risperidone in a cohort of patients newly diagnosed with 
schizophrenia (n=18), as well as untreated healthy controls (n=18) [Xuan et al., 2012]. Energy 
metabolism deficits in the form of increased glucose concentrations and decreased TCA pathway 
intermediates were present in drug-naïve patients. This has previously been proposed to be 
indicative of a metabolic syndrome/diabetes-like state in schizophrenia [Pickard, 2011, Harris et al., 
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2013]. The study also showed that monitoring changes in citrate (decr.), palmitic acid (decr.), myo-
inositol (incr.) and allantoin (incr.) offered the greatest discrimination between those with 
schizophrenia and healthy controls. Furthermore, myo-inositol, uric acid and tryptophan levels were 
perturbed after the commencement of risperidone treatment. The presence of uric acid and 
allantoin in these profiles may reflect a state of cellular oxidative stress. Interestingly, those patients 
who exhibited a therapeutic response to risperidone showed an increase in patient uric acid levels to 
those present in healthy controls.  This may be worthy of follow-up as a means to monitor or predict 
treatment outcome. The involvement of oxidative stress in schizophrenia is not as clearly defined as 
that for inflammation [Flatow et al.] but is strengthened by observations such as these. 
Another metabolomic study assessed serum samples from those with diagnoses of primary 
psychotic disorder (n=45), other non-affective psychosis (n=57), affective psychosis (n=37) and 
matched healthy controls [Oresic et al., 2011]. Increases in saturated tryglycerides, proline, 
glutamate, and lactate were observed  ? with a highly significant finding for proline seemingly 
restricted to a diagnosis of schizophrenia. The lipid/glutamate profile fits with an energy metabolism 
dysfunction in schizophrenia with compensatory up-regulation of fatty acid/ketone body 
metabolism. 
Still further support for this pathology comes from a metabolomic study of 112 schizophrenic 
patients and 110 healthy subjects, [Yang et al.]. Training and test sets identified glycerate (incr.), 
pyruvate (incr.), glutamate (incre.), 2-hydroxybutyrate (incr.), and myo-inostiol (incr.). However, 
citrate was shown to be increased in schizophrenia, in contrast to the findings of Xuan et al. 
described above. A combined classifier set of glycerate, eicosenoic acid, 2-hydroxybutyrate, pyruvate 
and cysteine profiles was found to be 90% accurate in diagnosing schizophrenia in the test set.  
 
Inflammation markers 
The findings detailed above suggest that schizophrenia has a biomarker profile that not only impacts 
of energy metabolism but is associated with dysfunction in the innate immune system and oxidative 
stress processes. The inflammatory component of schizophrenia has been recently reviewed [Michel 
et al., 2013] and, interestingly, can often show improvement with antipsychotic treatment. This has 
prompted studies that directly query inflammatory biomarker changes. 
A novel approach used a suite of biochemical and molecular assays to identify inflammatory 
pathologies in plasma and peripheral blood mononuclear cell samples from 117 patients recently 
diagnosed with schizophrenia and 106 matched controls applied  [Garcia-Bueno et al., 2013]. For 
NFʃɴ (incr.), iNOS (incr.), COX2 (incr.), Iʃɴɲ (decr.), and PPAR (decr.), changes were all indicative of 
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an active inflammatory response. A study of blood samples from 180 individuals with untreated 
schizophrenia and 380 matched healthy controls queried a panel of immunological and growth 
factor/hormone markers [Schwarz et al., 2014]. The case population showed a replicated division 
between those with altered immunological profiles and those with growth factor/hormone changes. 
This raises the prospect of pathological discrimination with potential for tailored treatments (see 
below).From the same laboratory, a recent survey of cytokine profiles in serum from 180 
antipsychotic-ŶĂŢǀĞĮƌƐƚ-episode schizophrenia patients and 350 healthy controls revealed increases 
in IL-1-RA , IL-10, and IL-15 cytokines [De Witte et al., 2014]. A meta-analysis of inflammatory 
cytokine production in first episode psychosis confirmed that there are significant increases for IL-6, 
IL-12, TNF-ɲ ? />-/ɴ ? />-8, TGF-ɴ ? />-1 RA. IFN-ɶ ?ĂĚƐ/>-2R, whereas the IL-10 cytokine is significantly 
reduced [Miller et al., 2011].  
 
Summary and future needs 
Despite evident methodological improvements, the transcriptomics studies have rarely found 
consistent specific gene biomarkers for illness. In that light, they can be considered more 
 ?ĚĞƐĐƌŝƉƚŝǀĞ ?ƚŚĂŶ ?ĚŝĂŐŶŽƐƚŝĐ ?ŝŶŽƵƚĐŽŵĞ ?dŚat aspect can be credited to the use of gene ontology 
enrichment statistics which, although limited by our relatively poor understanding of gene function, 
has repeatedly identified a set of aetiopathologies associated with schizophrenia that include energy 
metabolism, immune response and synaptic function. There is, however, still uncertainty whether 
these represent causes or consequences of the schizophrenia pathology. For example, the 
neurodevelopmental consequences of maternal immunological activation appear quite causative in 
nature, but it is much harder to categorise the adult chronic inflammatory state that is associated 
with schizophrenia (and neurodegenerative diseases). In order to consistently identify a set of 
biomarkers for schizophrenia, transcriptomics may need to approach the scale of sample numbers 
used in genomics [Schizophrenia Working Group of the Psychiatric Genomics, 2014]. This has a 
downside in that the need for large cohorts  reflects small effect sizes; and thus a requirement for 
diagnostics to be highly sensitive. Alternatively, new ways to disentangle environmentally-generated 
noise from disease state may be required. It is also vital that the public deposition and availability of 
microarray datasets continues, allowing researchers to take their particular panels of genes that 
discriminate disease status in their studies, and test them in a wider context. As with 
transcriptomics, there is perhaps an inevitability that the methylation field will also have to adopt 
genomics-level sample sizes  ? it is sobering to see results becoming less striking as sample numbers 
increase. 
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In this era of personalised medicine, it is important that biomarker findings from populations are 
verified and pursued at the level of the individual. An example where this has been successfully 
applied is the FINRISK study in which 17,345 individuals were assessed for blood biomarkers 
predicting short-term risk of mortality [Fischer et al., 2014]. Importantly, the four most powerful 
biomarkers; alpha-1-acid glycoprotein, albumin, very-low-density lipoprotein particle size, and 
citrate; ĐŽƵůĚďĞĐŽŵďŝŶĞĚƚŽĨŽƌŵĂ ?ƐƵŵŵĂƌǇƐĐŽƌĞ ? that had significant power to predict the risk 
of an individual ?Ɛ death within five years. It is reasonable to expect that schizophrenia sub-
classification and diagnosis will require similar combinatorial assessment of markers. However, it is 
probably fair to say that most current  ?-ŽŵŝĐƐ ? ĂŶĂůǇƐŝƐ ŝƐ ĐĂƌƌŝĞd out with a view to discern the 
 ?ŚŽƌŝǌŽŶƚĂů ?ƉŽƉƵůĂƚŝŽŶĂǀĞƌĂŐĞdifferences between cases and healthy controls  ? marker by marker. 
dŚĞŽƉƉŽƐŝƚĞ ? ?ǀĞƌƚŝĐĂů ? ?ĂƉƉƌŽĂĐŚĚĞŵĂŶĚƐŶĞǁǁĂǇƐŽĨĂŶĂůǇƐŝŶŐĚĂƚĂŝŶŽƌĚĞƌƚŽĚĞƚĞƌŵŝŶĞƚŚĞƐĞƚ
of genes that are contriďƵƚŝŶŐƚŽĂŶŝŶĚŝǀŝĚƵĂů ?ƐƌŝƐŬĂŶĚĞǆƉƌĞƐƐŝŽŶŽĨŝůůŶĞƐƐ ? These two analytical 
paradigms are presented in Figure 1. The occasional analytical approach [Wockner et al.] has 
attempted to define biomarker profiles for the individual and this may be a direction that more 
studies would profit from. One strategy to subtype individuals might be the targeted analysis of 
specific pathologies (for example, inflammation and energy metabolism) on order to guide selection 
of the best therapy. The development of mathematical strategies to identify and apply vertical bio-
/genomic marker subsets for schizophrenia characterisation, at the level of the individual, should be 
a research priority. 
 
[Figure 1 near here] 
Legend 
Figure 1 Two opposing schemes for biomarker analysis. In the more common horizontal approach 
the comparison is made between the case and control populations for each biomarker separately. 
This has statistical power to identify association but is confounded by heterogeneous intra-cohort 
disease structure. Our current knowledge of schizophrenia would suggest that a simple case-control 
split would not be possible due to the variable and combinatorial nature of aetiology and pathology 
in cases of schizophrenia. Therefore, a vertical approach might be preferable, which attempts to 
combine data from a subset of markers in an individual and compare this with similar subsets in 
other individuals. For example, the pairs of markers highlighted in A and B might define pathological 
aspects oĨ ĂŶ ŝŶĚŝǀŝĚƵĂů ?Ɛ ƐĐŚŝǌŽƉŚƌĞŶŝĂ ? Žƌ ƉŽƚĞŶƚŝĂů ƌĞƐƉŽŶƐĞƚŽ ƚƌĞĂƚŵĞŶƚ ?The issue with the 
vertical approach is that discovering the marker subsets is non-trivial as they have to expose 
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differences between schizophrenia and healthy controls as well as the internal discontinuities within 
schizophrenia. The horizontal approach can provide some aid in marker selection for the vertical 
approach but cannot realistically inform the more complex structure of individual risk.  
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